Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
International Journal of Cancer
|
February 7, 2022
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center
Elise F Nassif, Brandon Cope, Raymond Traweek, et al.
Frontiers in Immunology
|
May 15, 2025
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience
Madeline B Torres, Cheuk Hong Leung, Marianne Zoghbi, et al.
Molecular Carcinogenesis
|
November 27, 2024
Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1
Katarzyna Tomczak, Manishkumar S Patel, Angela D Bhalla, et al.
Annals of Surgical Oncology
|
August 24, 2023
Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy
Nolan M Winicki, Shannon N Radomski, Isabella S Florissi, et al.
ESMO Open
|
June 25, 2025
Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma
R S Traweek, M Zoghbi, R Lazcano, et al.
JAMA Network Open
|
February 28, 2024
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Mohammad A Zeineddine, et al.
Acta Neuropathologica
|
July 20, 2021
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state
Veena Kochat, Ayush T Raman, Sharon M Landers, et al.
Cancer Discovery
|
July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Kanwal Raghav, Suyu Liu, Michael J Overman, et al.
Frontiers in Oncology
|
October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcoma
Rossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Nature Cancer
|
February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
Christina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
International Journal of Cancer
|
February 7, 2022
Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center
Elise F Nassif, Brandon Cope, Raymond Traweek, et al.
Frontiers in Immunology
|
May 15, 2025
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience
Madeline B Torres, Cheuk Hong Leung, Marianne Zoghbi, et al.
Molecular Carcinogenesis
|
November 27, 2024
Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1
Katarzyna Tomczak, Manishkumar S Patel, Angela D Bhalla, et al.
Annals of Surgical Oncology
|
August 24, 2023
Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy
Nolan M Winicki, Shannon N Radomski, Isabella S Florissi, et al.
ESMO Open
|
June 25, 2025
Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma
R S Traweek, M Zoghbi, R Lazcano, et al.
JAMA Network Open
|
February 28, 2024
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Mohammad A Zeineddine, et al.
Acta Neuropathologica
|
July 20, 2021
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state
Veena Kochat, Ayush T Raman, Sharon M Landers, et al.
Cancer Discovery
|
July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Kanwal Raghav, Suyu Liu, Michael J Overman, et al.
Frontiers in Oncology
|
October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcoma
Rossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Nature Cancer
|
February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
Christina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Page
of 7